Tesamorelin
Also known as: Egrifta
Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.
Who's worth your money for Tesamorelin
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 35 scored sellers
$67.99 · 20mg · 99.8% purity
Best value after code
$0.15/mg effective with 15% code
$1.20 · 6.98mg · 98.5% purity
Most tested
13 independent COAs on file
$115 · 8mg · 99.7% purity
Average price
$7.59/mg
Sellers
89
45-day trend
-18.2%
78 of 89 sellers have a current price· 35 stale hidden· 8 unverified hidden
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · just now
$3.40/mg -55.2% vs avg$67.99
20mg
- 🇺🇸 Hydro Research Peptides97
✓ verified at source · just now
$0.17/mg -97.7% vs avg$1.20
6.98mg
- 🇺🇸 Moglabs96
✓ verified at source · just now
$10.00/mg +31.7% vs avg$50.00
5mg
- 🇺🇸 BioLongevity Labs96
✓ verified at source · just now
$14.38/mg +89.3% vs avg$115
8mg
- 🇺🇸 Reta One Labs95
✓ verified at source · just now
$3.90/mg -48.6% vs avg$39.00
10mg
- 🇺🇸 Licensed Peptides95
✓ verified at source · just now
$6.55/mg -13.7% vs avg$131
20mg
- 🇺🇸 Prime Peptides95
✓ verified at source · just now
$8.00/mg +5.4% vs avg$80.00
10mg
- Nova Peptides94
✓ verified at source · just now
$2.50/mg -67.1% vs avg$49.99
20mg
- 🇺🇸 Peptide Crafters94
✓ verified at source · just now
$5.53/mg -27.2% vs avg$55.25
10mg
- 🇺🇸 Forge Performance Co.94
✓ verified at source · just now
$6.00/mg -21% vs avg$60.00
10mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Tesamorelin
Get one email when the market actually moves — no newsletter, no noise.
About Tesamorelin
CAS
218949-48-5
Molecular formula
C221H366N72O67S
Sequence
YADAIFTNSY RKVLGQLSAR KLLQDIMSR QQGESNQERG ARARL
Typical dose range
2 mg/day subcutaneous (approved EGRIFTA); 1.4 mg/day (EGRIFTA SV); research use mirrors clinical dosing of 1–2 mg/day SC
Half-life
~26–38 minutes (Wikipedia / literature); FDA label reports ~8 minutes (single SC dose, healthy subjects)
COAs for Tesamorelin
314 third-party tests across 52 vendors. Each card links to the full report.
For
Tesamorelin
by Longeva· batch PM-260719-TESAMORELIN-01
For
Tesamorelin
by Virtus Peptides· batch NS-20260601 | TSM10-WHITE
For
Tesamorelin
by Peptide Plugs· batch 160-310X-DK
For
Tesamorelin
by NG Peptide· batch TSM-13
For
Tesamorelin
by Optima Supply· batch OS-2026-1763
For
Tesamorelin
by Hydro Research Peptides· batch HR-2026-4509
For
Tesamorelin
by optimasupply.is· batch OS-2026-1763
For
Tesamorelin
by Nova Peptides· batch NV-P-G8YE
For
Tesamorelin
by NG Peptide· batch tsm20-04
For
Tesamorelin
by Profound Aminos· batch Black Cap
For
Tesamorelin
by OROS Research· batch OR-LPTES10-626-B2
For
Tesamorelin
by Nova Peptides· batch NV-P-IPPF
For
Tesamorelin
by Peptide Partners· batch TES202607
For
Tesamorelin
by Voltera Sciences· batch TSM10-06022026
For
Tesamorelin
by Peptide Plugs· batch 136-02-SM-WT
For
Tesamorelin
by Polaris Peptides· batch POL-TESA10-9
For
Tesamorelin
by Blank Peptides· batch B-3699671-P
For
Tesamorelin
by Soma Peptides· batch TEX062641
For
Tesamorelin
by OROS Research· batch OR-LPTES5-626-B7
For
Tesamorelin
by Rescue Research USA· batch WP-TS-2606
For
Tesamorelin
by Sports Technology Labs· batch 2-1576-30
For
Tesamorelin
by Voltera Sciences· batch TSM10.05.28.26
For
Tesamorelin
by Verified Peptides· batch TM07261020J
For
Tesa
by Ion Peptide· batch TSM10-06022026
23 citations indexed for Tesamorelin
Study · 2026
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol
Background The Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH) study is a randomised controlled trial with the overall goal of examining the combined effect of exercise and the growth hormone-releasing hormone analogue tesamorelin on physical function.
case-report · 2026
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
Background Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI).
animal · 2026
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model
The introduction of combination antiretroviral therapy (cART) has significantly reduced AIDS-related morbidity and mortality. However, the prevalence of age-associated comorbidities, particularly cardiovascular diseases (CVD), has increased, becoming a leading cause of mortality in people living with HIV.
meta-analysis · 2026
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
Background HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks.
Study · 2026
P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants
meta-analysis · 2026
Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis
BackgroundHIV-associated lipodystrophy, a complication of combined antiretroviral therapy (CART), causes significant physical and psychological distress in people living with HIV (PLWH), compromising treatment adherence.